Selective cyclooxygenase inhibitors increase paclitaxel sensitivity in taxane-resistant ovarian cancer by suppressing P-glycoprotein expression
Open Access
- 1 January 2013
- journal article
- Published by Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology and Colposcopy in Journal of Gynecologic Oncology
- Vol. 24 (3) , 273-279
Abstract
Lee JP, et al. J Gynecol Oncol. 2013 Jul;24(3):273-279. https://doi.org/10.3802/jgo.2013.24.3.273Keywords
This publication has 20 references indexed in Scilit:
- Maximal cytoreductive effort in epithelial ovarian cancer surgeryJournal of Gynecologic Oncology, 2010
- Beyond chemotherapy: targeted therapies in ovarian cancerNature Reviews Cancer, 2009
- Structure, function and regulation of P-glycoprotein and its clinical relevance in drug dispositionXenobiotica, 2008
- An overview of cancer multidrug resistance: a still unsolved problemCellular and Molecular Life Sciences, 2008
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Impact of the Cyclooxygenase System on Doxorubicin-Induced Functional Multidrug Resistance 1 Overexpression and Doxorubicin Sensitivity in Acute Myeloid Leukemic HL-60 CellsThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Cyclooxygenase-2 gene induction causes CDDP resistance in colon cancer cell line, HCT-15.2004
- The epigenetics of ovarian cancer drug resistance and resensitizationAmerican Journal of Obstetrics and Gynecology, 2004
- Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian CarcinomaThe American Journal of Pathology, 2002
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002